Blinded CDCA 250 mg TID
Cheno-CTX-301
Phase 3 small_molecule completed
Quick answer
Blinded CDCA 250 mg TID for CTX is a Phase 3 program (small_molecule) at Mirum Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mirum Pharmaceuticals
- Indication
- CTX
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed